Bjorn Henning Gronberg, MD, PhD, on SCLC: Adjuvant Immunotherapy After CRT
2025 ASCO Annual Meeting
Bjorn Henning Gronberg, MD, PhD, of Norwegian University of Science and Technology (NTNU) and St. Olavs Hospital, presents phase II findings on the efficacy of atezolizumab after chemoradiotherapy (CRT) in limited-stage small cell lung cancer (SCLC) (LBA8005).
Transcript
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
We enrolled 216 patients at 37 hospitals in six countries of Europe, and out of those, 170 patients were randomized to receive either one year of atezolizumab or observation. The main endpoint was overall survival, and unfortunately we did not see any signal of an effect, neither for progression-free survival, so this is clearly a negative trial. Looking at subgroups, we do see that there are some differences in the effect depending on gender. Among women, patients on the observation arm lived much longer than expected, while among men there appears to be a signal of an effect. We also see that the choice of platinum had some influence on the survival curves. We see that among patients who received carboplatin, maybe there's a signal of an effect quite similar to what we actually saw also in the ADRIATIC trial. Median treatment time was 8 courses. Overall, there were more side effects in the experimental arm, but maybe not any single adverse event—it's more the totality. On the other hand, patients on the observation arm didn't meet the investigators as often as the patients who came regularly for infusions of atezolizumab. I think overall this study shows that the concept of adding checkpoint inhibitors after chemoradiated therapy in limited-stage small cell lung cancer is tolerable, even if this intervention did not prolong PFS or overall survival.
The ASCO Post Staff
Angela R. Bradbury, MD, of the University of Pennsylvania, presents findings from the eREACH trial—a randomized study of an eHEALTH delivery alternative for cancer genetic testing for hereditary predisposition in patients with metastatic cancers (Abstract 10502).
The ASCO Post Staff
South Florida has a unique demographic, characterized by a large Hispanic population with ancestries from the Caribbean and Central and South America. Arelis Esther Martir-Negron, MD, of Miami Cancer Institute, presents data from a retrospective analysis that sought to determine the frequency and spectrum of BRCA pathogenic/likely pathogenic variants in this population (Abstract 10579).
The ASCO Post Staff
Martin Reck, MD, PhD, of LungenClinic Grosshansdorf, Germany, discusses data from the phase III AEGEAN trial that studied perioperative durvalumab and neoadjuvant chemotherapy. Patients who were MRD-positive after surgery had significantly worse disease-free survival compared to MRD-negative patients. In addition, mutations in KEAP1 and KMT2C were associated with MRD positivity and reduced benefit from the regimen, identifying a small high-risk subgroup with poor prognosis (Abstract 8009).
The ASCO Post Staff
Sara M. Tolaney, MD, MPH, FASCO, of Dana-Farber Cancer Institute and Harvard Medical School, discusses findings from the phase III ASCENT-04/KEYNOTE-D19 study, which compared sacituzumab govitecan-hziy plus pembrolizumab vs chemotherapy plus pembrolizumab in previously untreated patients with PD-L1–positive advanced triple-negative breast cancer (TNBC) (LBA109).
The ASCO Post Staff
Suneel Deepak Kamath, MD, of the Cleveland Clinic, reports findings from a study that evaluated funding from the NIH and Congressionally Directed Medical Research Programs supporting lung, breast, colorectal, pancreatic, hepatobiliary, ovarian, cervical, endometrial, and prostate cancers, as well as leukemia, lymphoma, and melanoma, from 2013 to 2022 (Abstract 11025).
